Autolus Therapeutics (AUTL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mail
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.46), $0.04 worse than the analyst estimate of ($0.42).
For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norwegian Cruise Line (NCLH) Tops Q3 EPS by 19c; offers guidance
- Bunge Limited (BG) Tops Q3 EPS by 14c
- Brunswick (BC) Tops Q3 EPS by 22c, Misses on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
